HDAC8 and neuroblastoma: Darwish et al. synthesised a series of PROTACs designed to selectively target HDAC8 for degradation in neuroblastoma cells, utilising a selective HDAC8 inhibitor as the basis for PROTAC design.66 PROTAC 14 was capable of dose-dependent HDAC8 degradation with a Dmax value (maximum percentage degradation) of 70% for HDAC8 at 10 μM and no degradation of HDAC1 or HDAC6 was observed.